Speedus Corp. (SPDE)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Speedus Corp. (SPDE) ist im Communication Services-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erreicht einen hohen Ueberzeugungsscore von 72/100 ueber fundamentale, technische und Stimmungsfaktoren.
Zuletzt analysiert: 16. März 2026Speedus Corp. (SPDE) Medien- & Kommunikationsprofil
Speedus Corp. operates within the telecommunications services sector, providing diagnostic decision support tools for healthcare professionals. Their offerings include computer-aided medical devices, telemedicine delivery systems, and ultra-high-speed storage systems. Additionally, they possess an FCC commercial operating license and maintain investments in various securities.
Investmentthese
Speedus Corp. presents a speculative investment opportunity due to its presence in both the healthcare technology and telecommunications sectors. The company's gross margin of 63.9% indicates potential profitability if sales can be scaled. However, the negative P/E ratio and a profit margin of -616.6% highlight significant challenges in achieving profitability. The company's high beta of 35.48 suggests extreme volatility relative to the market. Growth catalysts include potential expansion of its telemedicine services and monetization of its FCC license. Investors should carefully consider the risks associated with OTC-listed companies and the company's current financial performance.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross Margin of 63.9% suggests potential for profitability if revenue increases.
- Negative Profit Margin of -616.6% indicates significant challenges in achieving profitability.
- Beta of 35.48 suggests the stock is highly volatile compared to the overall market.
- The company holds a local multipoint distribution service license, granting access to a spectrum in the New York City area.
- The company's focus on diagnostic decision support products and services positions it within the growing healthcare technology market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary diagnostic technology (Zargis Cardioscan).
- FCC license providing spectrum access in New York City.
- Established relationships with healthcare professionals.
- Diversified revenue streams (medical devices, storage systems, investments).
Schwaechen
- Negative profit margins and lack of profitability.
- High beta indicating significant stock volatility.
- Limited market presence compared to larger competitors.
- Dependence on regulatory approvals for medical devices.
Katalysatoren
- Upcoming: Potential FDA approval for new diagnostic devices.
- Ongoing: Expansion of telemedicine services to new geographic areas.
- Ongoing: Strategic partnerships with hospitals and clinics.
- Upcoming: Monetization of FCC license through partnerships or service development.
Risiken
- Ongoing: Negative profit margins and lack of profitability.
- Potential: Intense competition from established players.
- Potential: Technological obsolescence of diagnostic devices.
- Ongoing: Limited liquidity and trading volume due to OTC listing.
- Potential: Changes in healthcare regulations and reimbursement policies.
Wachstumschancen
- Expansion of Telemedicine Services: The increasing adoption of telemedicine presents a significant growth opportunity for Speedus Corp. The company's ZargisTelemed portal can be expanded to offer a wider range of remote diagnostic services, catering to the growing demand for convenient and accessible healthcare solutions. The global telemedicine market is projected to reach $400 billion by 2027, providing a substantial market for Speedus to tap into.
- Monetization of FCC License: Speedus Corp.'s local multipoint distribution service license in the New York City area represents a valuable asset. The company can explore opportunities to monetize this license through partnerships with telecommunications providers or by developing its own wireless broadband services. The demand for spectrum in densely populated areas like New York City is high, potentially leading to significant revenue generation.
- Strategic Partnerships in Healthcare: Collaborating with hospitals, clinics, and other healthcare providers can accelerate the adoption of Speedus Corp.'s diagnostic decision support tools. These partnerships can provide access to a wider patient base and facilitate the integration of Speedus's technology into existing healthcare workflows. The healthcare IT market is expected to reach $390 billion by 2024, offering ample opportunities for strategic alliances.
- Development of AI-Powered Diagnostics: Integrating artificial intelligence (AI) into Speedus Corp.'s diagnostic devices can enhance their accuracy and efficiency. AI algorithms can analyze patient data to identify patterns and predict potential health risks, enabling earlier and more effective interventions. The AI in healthcare market is projected to reach $45 billion by 2026, creating a significant opportunity for Speedus to leverage AI technologies.
- Expansion into International Markets: While currently focused on the United States, Speedus Corp. can explore opportunities to expand its operations into international markets. The demand for telemedicine and remote diagnostic solutions is growing globally, particularly in developing countries with limited access to healthcare services. This expansion could significantly increase Speedus's revenue and market share.
Chancen
- Expansion of telemedicine services.
- Monetization of FCC license through partnerships.
- Strategic alliances with hospitals and clinics.
- Development of AI-powered diagnostic tools.
Risiken
- Intense competition from established players.
- Technological obsolescence of diagnostic devices.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn affecting healthcare spending.
Wettbewerbsvorteile
- Proprietary diagnostic technology (Zargis Cardioscan, Signal X6).
- FCC commercial operating license providing exclusive spectrum access in the New York City area.
- Established relationships with healthcare professionals.
- Portfolio of marketable securities and investments.
Ueber SPDE
Founded in 1995 and based in Freehold, New Jersey, Speedus Corp. (formerly SPEEDUS.COM, Inc.) has evolved into a developer of diagnostic decision support products and services. The company targets primary care physicians, pediatricians, cardiologists, and other healthcare professionals in the United States. Its core offerings include computer-aided medical devices and telemedicine-based delivery systems. Key products are the Zargis Cardioscan device, a non-invasive diagnostic tool that analyzes acoustical data to detect potential heart murmurs; the ZargisTelemed portal; and the Signal X6 device, which records heart and lung sounds using acoustic sensors. Beyond healthcare, Speedus also develops and markets ultra-high-speed storage systems, including the JetX10 acceleration appliance, JetPod, and JetNode expansion chassis, designed for server networks and other applications. Furthermore, Speedus holds a local multipoint distribution service license, granting it access to a significant spectrum in the New York City area. The company also maintains a portfolio of marketable securities and investments in non-publicly held companies.
Was das Unternehmen tut
- Develops computer-aided medical devices for healthcare professionals.
- Offers telemedicine-based delivery systems for remote diagnostics.
- Provides the Zargis Cardioscan device for detecting heart murmurs.
- Offers the ZargisTelemed portal for remote patient monitoring.
- Markets the Signal X6 device for recording heart and lung sounds.
- Develops ultra-high-speed storage systems for server networks.
- Holds a local multipoint distribution service license in the New York City area.
- Invests in marketable securities and non-publicly held companies.
Geschaeftsmodell
- Sales of diagnostic medical devices and related software.
- Subscription fees for telemedicine portal access.
- Revenue from ultra-high-speed storage systems sales.
- Potential revenue from monetization of FCC license.
- Income from investments in marketable securities.
Branchenkontext
Speedus Corp. operates in the telecommunications services industry, which is undergoing rapid transformation driven by technological advancements and increasing demand for bandwidth. The healthcare technology segment, where Speedus offers diagnostic tools, is also experiencing growth due to the increasing adoption of telemedicine and remote patient monitoring. The company faces competition from established players in both sectors. Competitors include companies like ALVRQ (Allied Healthcare International Inc.) and AMRU (American Resources Corporation). The industry is characterized by intense competition and the need for continuous innovation.
Wichtige Kunden
- Primary care physicians
- Pediatricians
- Cardiologists
- Hospitals and clinics
- Telecommunications companies (potential FCC license customers)
Finanzdaten
Chart & Info
Speedus Corp. (SPDE) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer SPDE verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer SPDE.
Kursziele
Wall-Street-Kurszielanalyse fuer SPDE.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von SPDE auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Shant S. Hovnanian
CEO
Shant S. Hovnanian serves as the CEO of Speedus Corp. His background includes experience in managing and developing technology-driven companies. He has been involved in various aspects of business development, strategic planning, and financial management. His expertise lies in identifying and capitalizing on emerging market opportunities, particularly in the healthcare and telecommunications sectors. He is responsible for overseeing the overall direction and operations of the company.
Erfolgsbilanz: Under Shant S. Hovnanian's leadership, Speedus Corp. has focused on developing and marketing innovative diagnostic solutions for healthcare professionals. He has guided the company through various stages of growth and development, including the expansion of its product portfolio and the pursuit of strategic partnerships. His tenure has been marked by a commitment to technological innovation and customer satisfaction.
SPDE OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Speedus Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosures and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the potential for limited liquidity and transparency.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Higher volatility and price fluctuations.
- Limited liquidity and difficulty in trading shares.
- Greater regulatory scrutiny and potential for delisting.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and shareholder base.
- Monitor news and information about the company from reputable sources.
- Consult with a qualified financial advisor before investing.
- The company has been in operation since 1995.
- The company holds an FCC commercial operating license.
- The company has developed and marketed diagnostic medical devices.
- The company has a CEO with relevant experience in the technology sector.
Haeufige Fragen zu SPDE
What are the key factors to evaluate for SPDE?
Speedus Corp. (SPDE) currently holds an AI score of 72/100, indicating high score. Key strength: Proprietary diagnostic technology (Zargis Cardioscan).. Primary risk to monitor: Ongoing: Negative profit margins and lack of profitability.. This is not financial advice.
How frequently does SPDE data refresh on this page?
SPDE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SPDE's recent stock price performance?
Recent price movement in Speedus Corp. (SPDE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary diagnostic technology (Zargis Cardioscan).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SPDE overvalued or undervalued right now?
Determining whether Speedus Corp. (SPDE) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SPDE?
Before investing in Speedus Corp. (SPDE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SPDE to a portfolio?
Potential reasons to consider Speedus Corp. (SPDE) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary diagnostic technology (Zargis Cardioscan).. Additionally: FCC license providing spectrum access in New York City.. The AI-driven MoonshotScore of 72/100 reflects strong quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of SPDE?
Yes, most major brokerages offer fractional shares of Speedus Corp. (SPDE) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SPDE's earnings and financial reports?
Speedus Corp. (SPDE) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for SPDE earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.